datasheet1_NRF2 -617 C/A Polymorphism Impacts Proinflammatory Cytokine Levels, Survival, and Transplant-Related Mortality After Hematopoietic Stem Cell Transplantation in Adult Patients Receiving Busulfan-Based Conditioning Regimens.xls
Busulfan (BU) is widely used in conditioning regimens prior to hematopoietic stem cell transplantation (HSCT). The exposure-escalated BU directed by therapeutic drug monitoring (TDM) is extremely necessary for the patients with high-risk hematologic malignancies in order to diminish relapse, but it increases the risk of drug-induced toxicity. BU exposure, involved in the glutathione- (GSH-) glutathione S-transferases (GSTs) pathway and proinflammatory response, is associated with clinical outcomes after HSCT. However, the expression of genes in the GSH-GSTs pathway is regulated by NF-E2-related factor 2 (Nrf2) that can also alleviate inflammation. In this study, we evaluated the influence of NRF2 polymorphisms on BU exposure, proinflammatory cytokine levels, and clinical outcomes in HSCT patients. A total of 87 Chinese adult patients receiving twice-daily intravenous BU were enrolled. Compared with the patients carrying wild genotypes, those with NRF2 -617 CA/AA genotypes showed higher plasma interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-α levels, poorer overall survival (OS; RR = 3.91), and increased transplant-related mortality (TRM; HR = 4.17). High BU exposure [area under the concentration-time curve (AUC) > 9.27 mg/L × h)] was related to BU toxicities. Furthermore, NRF2 -617 CA/AA genotypes could significantly impact TRM (HR = 4.04; p = 0.0142) and OS (HR = 3.69; p = 0.0272) in the patients with high BU AUC. In vitro, we found that high exposure of endothelial cell (EC) to BU, in the absence of Nrf2, elicited the hyperstimulation of NF-κB-p65, accompanied with the elevated secretion of proinflammatory cytokines, and led to EC death. These results showed that NRF2 -617 CA/AA genotypes, correlated with high proinflammatory cytokine levels, could predict inferior outcomes in HSCT patients with high BU AUC. Thus, NRF2 -617 CA/AA genotyping combined with TDM would further optimize personalized BU dosing for sufficient efficacy and safety endpoint.
History
References
- https://doi.org//10.1016/j.bbmt.2010.06.017
- https://doi.org//10.1038/bmt.2016.322
- https://doi.org//10.1016/S2352-3026(16)30114-4
- https://doi.org//10.1182/blood.v85.11.3005.bloodjournal85113005
- https://doi.org//10.1007/s00280-014-2571-0
- https://doi.org//10.3324/haematol.2013.089888
- https://doi.org//10.1007/s11095-016-1927-z
- https://doi.org//10.1182/blood-2013-08-519009
- https://doi.org//10.1007/s00280-004-0922-y
- https://doi.org//10.1159/000028359
- https://doi.org//10.1016/S0009-9236(03)00190-5
- https://doi.org//10.1146/annurev.genom.2.1.9
- https://doi.org//10.1097/00007890-197410000-00001
- https://doi.org//10.1016/j.bbmt.2019.09.033
- https://doi.org//10.1002/jcph.1354
- https://doi.org//10.3389/fgene.2014.00383
- https://doi.org//10.1073/pnas.0705971104
- https://doi.org//10.1007/BF0325642010.2165/11592520-000000000-00000
- https://doi.org//10.1038/bmt.2016.283
- https://doi.org//10.1096/fj.06-7759com
- https://doi.org//10.1111/cas.12436
- https://doi.org//10.1038/sj.bmt.1703258
- https://doi.org//10.1080/17425255.2017.1360277
- https://doi.org//10.1053/jhep.2002.33995
- https://doi.org//10.1074/jbc.%20R900010200
- https://doi.org//10.3109/10428194.2010.520773
- https://doi.org//10.1016/j.bbmt.2016.07.013
- https://doi.org//10.18632/oncotarget.10988
- https://doi.org//10.1038/s41409-018-0281-7
- https://doi.org//10.1038/ncomms11624
- https://doi.org//10.1038/srep17828
- https://doi.org//10.1038/s41409-019-0579-0
- https://doi.org//10.1016/j.bbmt.2015.07.016
- https://doi.org//10.1016/0002-9343(80)90380-0
- https://doi.org//10.1055/s-0035-1556728
- https://doi.org//10.1042/BST20150014
- https://doi.org//10.1016/j.intimp.2018.06.029
- https://doi.org//10.1038/bmt.2015.14
CC BY 4.0